NPI: 1609843101 · FT LAUDERDALE, FL 33304 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/02/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/02/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 11,833 | $1.20M |
| 2019 | 15,827 | $899K |
| 2020 | 154 | $24K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 10,930 | 355 | $868K |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 7,026 | 411 | $581K |
| J1270 | Injection, doxercalciferol, 1 mcg | 5,519 | 306 | $309K |
| A4657 | Syringe, with or without needle, each | 944 | 396 | $141K |
| 83550 | 494 | 259 | $40K | |
| 83540 | 499 | 259 | $40K | |
| 83970 | 392 | 185 | $28K | |
| 82728 | 359 | 205 | $28K | |
| 85041 | 445 | 192 | $25K | |
| 85048 | 445 | 192 | $25K | |
| J1756 | Injection, iron sucrose, 1 mg | 447 | 81 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 195 | 87 | $12K |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 119 | 38 | $8K |